All posts tagged
Update: Transgene and BMS Upgrade their Lung Cancer Combination to First Line
Do PD-1 and PD-L1 Checkpoint Inhibitors Live Up to Their Hype?
Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Will BMS Take Over a Danish Biotech in a Massive €400M Deal?
More News! Will BMS be acquired? “CRISPR babies aren’t unethical”?
French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial
World Cancer Day is Saturday! Europe’s Oncology in Numbers
A Combination of Checkpoint Inhibitors triggers new Milestone Payment
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
BMS Offers €850M for a British Oncolytic Virus better than CAR-T
Microbiomics recruited for Immuno-Oncology in a Huge New Partnership
Results from 45% of Clinical Trials are kept Secret
Labiotech UG, All Rights Reserved -
Send this to a friend